Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? - PubMed (original) (raw)
Review
. 2010 May-Jun;4(3):152-5.
doi: 10.1016/j.jacl.2010.03.005. Epub 2010 Mar 18.
Affiliations
- PMID: 21122647
- DOI: 10.1016/j.jacl.2010.03.005
Review
Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?
Allan Sniderman et al. J Clin Lipidol. 2010 May-Jun.
Abstract
Low-density lipoprotein cholesterol (LDL-C) has been the focus of managing lipoprotein disorders for decades. It is now time to consider a change. Both apolipoprotein B (apoB) and non-high-density lipoprotein cholesterol (HDL-C) have been shown to be more accurate markers of cardiovascular risk than LDL-C. ApoB measures total atherogenic particle number, of which 90% are LDL particles. Therefore, LDL particle number determines plasma apoB in most patients. Non-HDL-C is widely assumed to be superior to LDL-C when triglyceride concentrations are elevated (even modestly) because it includes the cholesterol in very-low-density lipoprotein. However, evidence does not support this concept. Rather, non-HDL-C appears to be an indirect way of estimating apoB. We argue that we should integrate the information from non-HDL-C and apoB for better risk assessment and a better target of therapy.
Copyright © 2010 National Lipid Association. Published by Elsevier Inc. All rights reserved.
Comment in
- Re: Superiority of apolipoprotein B (apoB) over low-density lipoprotein cholesterol (LDL-C) in treatment of hyperlipidemia.
Mickle JD Jr. Mickle JD Jr. J Clin Lipidol. 2010 Jul-Aug;4(4):317. doi: 10.1016/j.jacl.2010.06.006. Epub 2010 Jul 8. J Clin Lipidol. 2010. PMID: 21122669 No abstract available.
Similar articles
- Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO, Borlaug BA, Johnston PV, Kral BG, Rouf R, Blumenthal RS, Kwiterovich PO Jr. Mudd JO, et al. J Am Coll Cardiol. 2007 Oct 30;50(18):1735-41. doi: 10.1016/j.jacc.2007.07.045. Epub 2007 Oct 15. J Am Coll Cardiol. 2007. PMID: 17964036 - [What is a good marker for serum cholesterol to identify high-risk patients at general health checks?].
Fujioka Y. Fujioka Y. Rinsho Byori. 2012 Apr;60(4):328-35. Rinsho Byori. 2012. PMID: 22686042 Japanese. - Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
Boumaiza I, Omezzine A, Rejeb J, Rebhi L, Kalboussi N, Ben Rejeb N, Nabli N, Ben Abdelaziz A, Boughazala E, Bouslama A. Boumaiza I, et al. Metab Syndr Relat Disord. 2010 Dec;8(6):515-22. doi: 10.1089/met.2010.0006. Epub 2010 Aug 17. Metab Syndr Relat Disord. 2010. PMID: 20715933 Clinical Trial. - Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease.
Miller M, Ginsberg HN, Schaefer EJ. Miller M, et al. Am J Cardiol. 2008 Apr 1;101(7):1003-8. doi: 10.1016/j.amjcard.2007.11.046. Am J Cardiol. 2008. PMID: 18359322 Review. - The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment.
Andrikoula M, McDowell IF. Andrikoula M, et al. Diabetes Obes Metab. 2008 Apr;10(4):271-8. doi: 10.1111/j.1463-1326.2007.00714.x. Diabetes Obes Metab. 2008. PMID: 18333887 Review.
Cited by
- Association between non-high-density lipoprotein cholesterol and haemorrhagic transformation in patients with acute ischaemic stroke.
Wang Y, Song Q, Cheng Y, Wei C, Ye C, Liu J, Wu B, Liu M. Wang Y, et al. BMC Neurol. 2020 Feb 7;20(1):47. doi: 10.1186/s12883-020-1615-9. BMC Neurol. 2020. PMID: 32033596 Free PMC article. - A new ratio for better predicting future death/myocardial infarction than standard lipid measurements in women >50 years undergoing coronary angiography: the apolipoprotein A1 remnant ratio (Apo A1/ [VLDL₃+IDL]).
May HT, Nelson JR, Kulkarni KR, Anderson JL, Horne BD, Bair TL, Muhlestein JB. May HT, et al. Lipids Health Dis. 2013 Apr 26;12:55. doi: 10.1186/1476-511X-12-55. Lipids Health Dis. 2013. PMID: 23621905 Free PMC article. - A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M. Alla VM, et al. Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9. Drugs. 2013. PMID: 23754124 Review. - Comparison of various lipid variables as predictors of coronary heart disease in Japanese men and women with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study.
Sone H, Tanaka S, Tanaka S, Iimuro S, Ishibashi S, Oikawa S, Shimano H, Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Sone H, et al. Diabetes Care. 2012 May;35(5):1150-7. doi: 10.2337/dc11-1412. Epub 2012 Feb 14. Diabetes Care. 2012. PMID: 22338107 Free PMC article. - Associations of non-HDL-C and triglyceride/HDL-C ratio with coronary plaque burden and plaque characteristics in young adults.
Akin F, Altun İ, Ayca B, Kose N, Altun İ. Akin F, et al. Bosn J Basic Med Sci. 2022 Oct 23;22(6):1025-1032. doi: 10.17305/bjbms.2022.7142. Bosn J Basic Med Sci. 2022. PMID: 35531978 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous